NEW YORK (GenomeWeb) – CareDx went public today with an initial public offering of 4 million shares of common stock at $10 per share.

The Brisbane, Calif.-based molecular diagnostics firm's began trading its shares on the Nasdaq under ticker symbol "CDNA". The $10 share price falls short of an earlier range of $15 to $17 per share that it said it anticipated fetching.

CareDx's shares were trading at $9.30 on Friday morning.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.